Supernus, Inc. Common Stock (SUPN) Financials
Key financial figures for Supernus, Inc. Common Stock (Q3 2026).
Supernus posts record Q3 2026 revenue of $226.8M (+18%), raises 2026 revenue guidance to $875-900M, and expects the Indivior merger to close November 2, 2026. Total revenues were a record $226.8M, up 18% from $192.1M; the four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) totaled $192.2M, up 29%. GAAP net earnings were $20.9M ($0.35 per diluted share) vs a net loss of $45.1M ($0.80 per share) a year earlier; GAAP EPS of $0.35 is below the $0.49 FMP estimate, while revenue beat the $217.6M FMP estimate (estimate basis not stated). Adjusted operating earnings (non-GAAP) were $55.2M vs $41.9M; cash and current marketable securities were about $359.5M. On the outlook: FY2026 total revenues $875-900M (previous $860-890M); GAAP operating earnings $(5)-$(40)M (previous $(20)-$(50)M); adjusted operating earnings (non-GAAP) $160-180M (previous $150-180M). The release states this guidance will no longer apply if the Indivior merger closes on November 2, 2026. Figures are for Q3 2026, as Supernus Pharmaceuticals Inc. reported them.
- Revenue
- $356M
- Net Income
- $137M
- EPS
- $1.16
- Total Assets
- $1.3B
- Operating Cash Flow
- $97M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $356M | $137M | $1.12 | 50.84% | $83M |
| Q2 FY2026 | $343M | $122M | $0.98 | 46.65% | $222M |
| Q1 FY2026 | $317M | $89M | $0.69 | 43.22% | -$29M |
| Q4 FY2025 | $358M | $102M | $0.82 | 34.08% | -$245M |
| Q3 FY2025 | $314M | $42M | $0.33 | 31.53% | -$59M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.2B | $210M | $1.64 | 21.39% | -$94M |
| FY2024 | $1.2B | $2M | $0.05 | 2.69% | $5M |
| FY2023 | $1.1B | -$129M | -$0.92 | -14.27% | -$353M |
Frequently asked questions
What was Supernus Pharmaceuticals Inc.'s revenue last quarter?
Supernus Pharmaceuticals Inc. reported revenue of $356.0 million for Q3 FY2026, up 13.4% from the same period a year earlier.
Is Supernus Pharmaceuticals Inc. profitable?
Yes. Supernus Pharmaceuticals Inc. reported net income of $137.0 million for Q3 FY2026, a net margin of 38.48% on revenue.
How has Supernus Pharmaceuticals Inc.'s margin trended?
Operating margin was 50.84% in Q3 FY2026, compared with 31.53% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Supernus Pharmaceuticals Inc. generate?
Supernus Pharmaceuticals Inc. generated free cash flow of $83.0 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Supernus, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.